Gut and Liver 2010; 4(1): 15-24 https://doi.org/10.5009/gnl.2010.4.1.15 Management of Chronic Hepatitis B with Nucleoside or Nucleotide Analogues: A Review of Current Guidelines
Author Information
Moon Seok Choi and Byung Chul Yoo
Division of Gastroenterology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Byung Chul Yoo
© The Korean Society of Gastroenterology, the Korean Society of Gastrointestinal Endoscopy, the Korean Society of Neurogastroenterology and Motility, Korean College of Helicobacter and Upper Gastrointestinal Research, Korean Association the Study of Intestinal Diseases, the Korean Association for the Study of the Liver, Korean Pancreatobiliary Association, and Korean Society of Gastrointestinal Cancer. All rights reserved.

Abstract
Antiviral treatment of hepatitis B is one of the most rapidly evolving fields in current medicine. Guidelines for the management of chronic hepatitis B (CH-B) have been proposed and revised by many academic societies and groups. Recommendations for nucleoside or nucleotide analogue (NUC) therapy from representative current guidelines are compared herein with each other and with previous guidelines. Several differences among individual recommendations may reflect regional and temporal differences as well as differences in the available data upon which the guidelines are based. Nevertheless, these guidelines share a common principle regarding NUC treatment for CH-B: long-term viral suppression by the drugs with potent antiviral activity and low rate of development of drug resistance to prevent disease progression. A review of the past and current guidelines for the management of CH-B would be useful for evaluating the current status of management of the disease and to identify better solutions for improving the outcome of patients with CH-B. (Gut Liver 2010;4:15- 24)
Keywords: Chronic hepatitis B; Liver cirrhosis; Viral suppression; Management; Guideline
Abstract
Antiviral treatment of hepatitis B is one of the most rapidly evolving fields in current medicine. Guidelines for the management of chronic hepatitis B (CH-B) have been proposed and revised by many academic societies and groups. Recommendations for nucleoside or nucleotide analogue (NUC) therapy from representative current guidelines are compared herein with each other and with previous guidelines. Several differences among individual recommendations may reflect regional and temporal differences as well as differences in the available data upon which the guidelines are based. Nevertheless, these guidelines share a common principle regarding NUC treatment for CH-B: long-term viral suppression by the drugs with potent antiviral activity and low rate of development of drug resistance to prevent disease progression. A review of the past and current guidelines for the management of CH-B would be useful for evaluating the current status of management of the disease and to identify better solutions for improving the outcome of patients with CH-B. (Gut Liver 2010;4:15- 24)
Keywords: Chronic hepatitis B; Liver cirrhosis; Viral suppression; Management; Guideline
Search for
Services
Archives